Argatroban, a direct thrombin inhibitor for heparin-induced thrombocytopaenia: present and future perspectives

Bibliography

• DANIEL TO, GIBBS VC, MILFAY DF et al.: Thrombin stimulates c-sis gene expression in microvascular endothelial cells. J. Biol. Chem. (1986) 261(21):9579-9582.
   PubMed Web of Science ®Google Scholar
• WEKSLER BB, LEY CW, JAFFE EA: Stimulation of endothelial cell prostacyclin production by thrombin, trypsin, and the ionophore A 23187. J. Clin. Invest. (1978) 62(5):923-930.
   PubMed Web of Science ®Google Scholar
• PRESCOTT SM, ZIMMERMAN GA, MCINTYRE TM: Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when stimulated with thrombin. Proc. Natl. Acad. Sci. USA (1984) 81(11):3534-3538.
   PubMed Web of Science ®Google Scholar
• WHITE H: Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet (2001) 9296(358):1855-1863.
   Google Scholar
• CANNON CP, WEINTRAUB WS, DEMOPOULOS LA et al.: Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N. Engl. J. Med. (2001) 344(25):1879-1887.
   PubMed Web of Science ®Google Scholar
• HIRSH J, WARKENTIN TE, SHAUGHNESSY SG et al.: Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest (2001) 119(Suppl. 1):64S-94S.
   PubMed Web of Science ®Google Scholar
• WEITZ JI, BULLER HR: Direct thrombin inhibitors in acute coronary syndromes: present and future. Circulation (2002) 105(8):1004-1011.
   PubMed Web of Science ®Google Scholar
• YOUNG E, WELLS P, HOLLOWAY S et al.: Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb. Haemost. (1994) 71(3):300-304.
   PubMed Web of Science ®Google Scholar
• BATES SM, WEITZ JI: Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am. J. Cardiol. (1998) 82(8B):12P-18P.
   PubMed Web of Science ®Google Scholar
• YUSUF S, MEHTA SR, XIE C et al.: Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA (2005) 293(4):427-435.
   PubMed Web of Science ®Google Scholar
• BORENTAIN M, MONTALESCOT G, BOUZAMONDO A, et al.: Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis. Catheter. Cardiovasc. Interv. (2005) 65(2):212-221.
   PubMed Web of Science ®Google Scholar
• MICHOTA F, MERLI G: Anticoagulation in special patient populations: are special dosing considerations required? Cleve. Clin. J. Med. (2005) 72(Suppl. 1):S37-S42.
   PubMed Web of Science ®Google Scholar
• LOCKE CF, DOOLEY J, GERBER J: Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs. low molecular weight heparin in non-surgical patients are low and similar. Thromb. J. (2005) 3(1):4.
   PubMedGoogle Scholar
• PRANDONI P, SIRAGUSA S, GIROLAMI B, FABRIS F: The incidence of heparin-induced thrombocytopenia in medical patients treated with low molecular weight heparin. Blood (2005) 106(9):3049-3054.
   PubMed Web of Science ®Google Scholar
• WARKENTIN TE, ROBERTS RS, HIRSH J et al.: An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch. Intern. Med. (2003) 163(20):2518-2524.
   PubMed Web of Science ®Google Scholar
• KONG DF, TOPOL EJ, BITTL JA et al.: Clinical outcomes of bivalirudin for ischemic heart disease. Circulation (1999) 100(20):2049-2053.
   PubMed Web of Science ®Google Scholar
• Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Lancet (1999) 353(9151):429-438.
   PubMed Web of Science ®Google Scholar
• JOB H, INGRID J, TIVADAR F, LUKAS P: Treatment of patients with a history of heparin-induced thrombocytopenia and anti-lepirudin antibodies with argatroban. J. Thromb. Thrombolysis. (2005) 19(1):65-69.
   PubMed Web of Science ®Google Scholar
• WALENGA JM, AHMAD S, HOPPENSTEADT D et al.: Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb. Res. (2002) 105(5):401-405.
   PubMed Web of Science ®Google Scholar
• OKAMOTO S, HIJIKATA A, KIKUMOTO R et al.: Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion. Biochem. Biophys. Res. Commun. (1981) 101(2):440-446.
   PubMed Web of Science ®Google Scholar
• LEWIS BE, WALLIS DE, LEYA F et al.: Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch. Intern. Med. (2003) 163(15):1849-1856.
   PubMed Web of Science ®Google Scholar
• OWEN TJ, KRSTENANSKY JL, YATES MT, MAO SJ: N-terminal requirements of small peptide anticoagulants based on hirudin54-65. J. Med. Chem. (1988) 31(5):1009-1011.
   PubMed Web of Science ®Google Scholar
• BODE W, TURK D, STURZEBECHER J: Geometry of binding of the benzamidine- and arginine-based inhibitors N alpha-(2-naphthyl-sulphonyl-glycyl)-DL-p-amidinophenylalanyl-pipe ridine (NAPAP) and (2R,4R)-4-methyl-1-[N alpha-(3-methyl-1,2,3,4-tetrahydro-8- quinolinesulphonyl)-L-arginyl]-2-piperidine carboxylic acid (MQPA) to human alpha-thrombin. X-ray crystallographic determination of the NAPAP-trypsin complex and modeling of NAPAP-thrombin and MQPA-thrombin. Eur. J. Biochem. (1990) 193(1):175-182.
   PubMedGoogle Scholar
• KIKUMOTO R, TAMAO Y, TEZUKA T et al.: Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methy-1,2,3,4-tetrahydro-8-quinolinyl) sulfonyl]-l-arginyl)]-2-piperidinecarboxylic acid. Biochemistry (1984) 23(1):85-90.
   PubMed Web of Science ®Google Scholar
• OKAMOTO S, HIJIKATA-OKUNOMIYA A: Synthetic selective inhibitors of thrombin. Methods Enzymol. (1993) 222:328-340.
   PubMed Web of Science ®Google Scholar
• JESKE W, WALENGA JM, LEWIS BE, FAREED J: Pharmacology of argatroban. Expert. Opin. Investig. Drugs. (1999) 8(5):625-654.
   PubMedGoogle Scholar
• BANNER DW, HADVARY P: Inhibitor binding to thrombin: X-ray crystallographic studies. Adv. Exp. Med. Biol. (1993) 340:27-33.
   PubMedGoogle Scholar
• BAUER M, BRANDSTETTER H, TURK D, STURZEBECHER J, BODE W: Crystallographic determination of thrombin complexes with small synthetic inhibitors as a starting point for the receptor-based design of antithrombotics. Semin. Thromb. Hemost. (1993) 19(4):352-360.
   PubMed Web of Science ®Google Scholar
• BERRY CN, GIRARDOT C, LECOFFRE C, LUNVEN C: Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: Comparison with heparin and recombinant hirudin. Thromb. Haemost. (1994) 72(3):381-386.
   PubMed Web of Science ®Google Scholar
• LUNVEN C, GAUFFENY C, LECOFFRE C et al.: Inhibition by argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin. Thromb. Haemost. (1996) 75(1):154-160.
   PubMed Web of Science ®Google Scholar
• KLEIMAN NS: Clinical trials of conjunctive anticoagulant strategies in thrombolysis. Coron. Artery Dis. (1996) 7(7):508-515.
   PubMed Web of Science ®Google Scholar
• CLARKE RJ, MAYO G, FITZGERALD GA, FITZGERALD DJ: Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation (1991) 83(5):1510-1518.
   PubMed Web of Science ®Google Scholar
• EIDT JF, ALLISON P, NOBLE S et al.: Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J. Clin. Invest. (1989) 84(1):18-27.
   PubMed Web of Science ®Google Scholar
• TAMAO Y, YAMAMOTO T, KIKUMOTO R et al.: Effect of a selective thrombin inhibitor MCI-9038 on fibrinolysis in vitro and in vivo. Thromb. Haemost. (1986) 56(1):28-34.
   PubMed Web of Science ®Google Scholar
• JANG IK, GOLD HK, LEINBACH RC, FALLON JT, COLLEN D: In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. Circ. Res. (1990) 67(6):1552-1561.
   PubMed Web of Science ®Google Scholar
• HURSTING MJ, ALFORD KL, BECKER JC et al.: Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Semin. Thromb. Hemost. (1997) 23(6):503-516.
   PubMed Web of Science ®Google Scholar
• VERSTRAETE M: Modulating platelet function with selective thrombin inhibitors. Haemostasis (1996) 26(Suppl 4):70-77.
   PubMedGoogle Scholar
• HANTGAN RR, JEROME WG, HURSTING MJ: No effect of clot age or thrombolysis on argatroban's inhibition of thrombin. Blood (1998) 92(6):2064-2074.
   PubMed Web of Science ®Google Scholar
• NAGASHIMA H: Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. II. Effects on fibrinolysis. J. Biol. Chem. (2002) 277(52):50445-50449.
   PubMed Web of Science ®Google Scholar
• NAGASHIMA H: Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation. J. Biol. Chem. (2002) 277(52):50439-50444.
   PubMed Web of Science ®Google Scholar
• MIYAHARA S, KIRYU J, TSUJIKAWA A et al.: Argatroban attenuates leukocyte- and platelet-endothelial cell interactions after transient retinal ischemia. Stroke (2003) 34(8):2043-2049.
   PubMed Web of Science ®Google Scholar
• Encysive Pharmaceuticals, GlaxoSmithKline: Argatroban prescribing information, Encysive Pharmaceuticals, Bellaire (TX) USA and GlaxoSmithKline (NC) USA (2005).
   Google Scholar
• SWAN SK, HURSTING MJ: The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy (2000) 20(3):318-329.
   PubMed Web of Science ®Google Scholar
• AMIRAL J, BRIDEY F, DREYFUS M, VISSOC AM et al.: Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb. Haemost. (1992) 68(1):95-96.
   PubMed Web of Science ®Google Scholar
• WARKENTIN TE, GREINACHER A: Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 126(Suppl. 3):311S-337S.
   PubMedGoogle Scholar
• KOUIDES PA, FRICKE W: Diagnosis and management of heparin-induced thrombocytopenia. Expert. Rev. Cardiovasc. Ther. (2005) 3:335-345.
   PubMedGoogle Scholar
• LEWIS BE, WALLIS DE, BERKOWITZ SD et al.: Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation (2001) 103(14):1838-1843.
   PubMed Web of Science ®Google Scholar
• HALLMAN SE, HEBBAR L, ROBISON J, UBER WE: The use of argatroban for carotid endarterectomy in heparin-induced thrombocytopenia. Anesth. Analg. (2005) 100(4):946-948.
   PubMed Web of Science ®Google Scholar
• LEWIS BE, MATTHAI WH JR, COHEN M et al.: Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter. Cardiovasc. Interv. (2002) 57(2):177-184.
   PubMed Web of Science ®Google Scholar
• JANG IK, LEWIS BE, MATTHAI WH JR, KLEIMAN NS: Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, nonrandomized pilot study. J. Thromb. Thrombolysis (2004) 18(1):31-37.
   PubMed Web of Science ®Google Scholar
• ITOH T, NONOGI H, MIYAZAKI S et al.: Local delivery of argatroban for the prevention of restenosis after coronary balloon angioplasty: a prospective randomized pilot study. Circ. J. (2004) 68(7):615-622.
   PubMed Web of Science ®Google Scholar
• VERMEER F, VAHANIAN A, FELS PW et al.: Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI Study. J. Thromb. Thrombolysis (2000) 10(3):233-240.
   PubMed Web of Science ®Google Scholar
• JANG IK, BROWN DF, GIUGLIANO RP et al.: A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. J. Am. Coll. Cardiol. (1999) 33(7):1879-1885.
   PubMed Web of Science ®Google Scholar
• LAMONTE MP: Argatroban in thrombotic stroke. Pathophysiol. Haemost. Thromb. (2002) 32(Suppl. 3):39-45.
   PubMedGoogle Scholar
• LAMONTE MP, NASH ML, WANG DZ et al.: Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study. Stroke (2004) 35(7):1677-1682.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI S, TAZAKI Y: Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. Semin. Thromb. Hemost. (1997) 23(6):531-534.
   PubMed Web of Science ®Google Scholar